The US Food and Drug Administration (FDA) has cleared Respiratory Motion's non-invasive respiratory monitor, designed for monitoring breathing abnormalities often associated with potentially lethal respiratory depression.
By applying a chest sensor to the patient, the ExSpiron monitoring system measures and displays data of lung volume against time, minute ventilation (the amount of air that enters/leaves the lungs every minute), respiratory rate (breaths per minute), and tidal volume (the volume of air in a single breath).
The data provided will enable healthcare clinicians to detect the changes earlier and reduce serious events including respiratory depression and cardiopulmonary arrest.
Respiratory depression occurs partly in response to medications such as narcotic painkillers and sedatives commonly administered after surgery, according to the company.
Respiratory Motion CEO Jenny Freeman said the company had been created to develop technologies to assist clinicians in their fight against respiratory depression and help improve patient safety.
"As a cardiothoracic surgeon, I am all too aware of the grave threat that respiratory depression presents post-operatively or in other scenarios where respiration is compromised such as with opioid therapy or in certain disease states," she said.
"Respiratory Motion's ExSpiron provides the same volume metrics that physicians have come to rely on to manage patients on mechanical ventilators.
"We have seen significant physician interest in our technology and are pleased to be providing a new, quantitative tool to help address this critically important challenge that is faced every day in caring for patients following surgery."
Vidant Healthcare anesthesiologist and Respiratory Motion clinical advisor Gary John Mullen said: "The ExSpiron will help nurses and care teams keep a constant watch on the high volume of patients under their care and feed them real-time, quantitative data as an important adjunct to patient assessment and decision making."
Image: ExSpiron monitor allows clinicians to monitor breathing abnormalities often associated with potentially lethal respiratory depression. Photo: courtesy of Business Wire.